Suppr超能文献

未经治疗的正常眼压性青光眼患者与经治疗眼压降低的患者之间青光眼进展情况的比较。协作性正常眼压性青光眼研究组。

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

出版信息

Am J Ophthalmol. 1998 Oct;126(4):487-97. doi: 10.1016/s0002-9394(98)00223-2.

Abstract

PURPOSE

To determine if intraocular pressure plays a part in the pathogenic process of normal-tension glaucoma.

METHODS

One eye of each eligible subject was randomized either to be untreated as a control or to have intraocular pressure lowered by 30% from baseline. Eyes were randomized if they met criteria for diagnosis of normal-tension glaucoma and showed documented progression or high-risk field defects that threatened fixation or the appearance of a new disk hemorrhage. The clinical course (visual field and optic disk) of the group with lowered intraocular pressure was compared with the clinical course when intraocular pressure remained at its spontaneous untreated level.

RESULTS

One hundred-forty eyes of 140 patients were used in this study. Sixty-one were in the treatment group, and 79 were untreated controls. Twenty-eight (35%) of the control eyes and 7 (12%) of the treated eyes reached end points (specifically defined criteria of glaucomatous optic disk progression or visual field loss). An overall survival analysis showed a statistically significant difference between the two groups (P < .0001). The mean survival time +/-SD of the treated group was 2,688 +/- 123 days and for the control group, 1,695 +/- 143 days. Of 34 cataracts developed during the study, 11 (14%) occurred in the control group and 23 (38%) in the treated group (P = .0075), with the highest incidence in those whose treatment included filtration surgery.

CONCLUSIONS

Intraocular pressure is part of the pathogenic process in normal-tension glaucoma. Therapy that is effective in lowering intraocular pressure and free of adverse effects would be expected to be beneficial in patients who are at risk of disease progression.

摘要

目的

确定眼压是否在正常眼压性青光眼的致病过程中起作用。

方法

将符合条件的每个受试者的一只眼睛随机分为两组,一组不进行治疗作为对照,另一组将眼压从基线水平降低30%。如果眼睛符合正常眼压性青光眼的诊断标准,并且有记录显示病情进展或存在威胁固视的高危视野缺损或出现新的视盘出血,则将其纳入随机分组。将眼压降低组的临床病程(视野和视盘)与眼压保持在自然未治疗水平时的临床病程进行比较。

结果

本研究共纳入140例患者的140只眼睛。治疗组61只,未治疗对照组79只。对照组中有28只眼睛(35%)和治疗组中有7只眼睛(12%)达到终点(具体定义的青光眼性视盘进展或视野丧失标准)。总体生存分析显示两组之间存在统计学显著差异(P <.0001)。治疗组的平均生存时间±标准差为2688±123天,对照组为1695±143天。在研究期间发生的34例白内障中,11例(14%)发生在对照组,23例(38%)发生在治疗组(P =.0075),其中治疗包括滤过手术的患者发病率最高。

结论

眼压是正常眼压性青光眼致病过程的一部分。预计有效降低眼压且无不良反应的治疗方法对有疾病进展风险的患者有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验